| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. TAU-2212 binds an exclusively quaternary epitope, and exhibits a unique, flexible mode of neutralization that involves transitioning between five different conformations, with both arms of the antibody recruited for cross linking intra- and inter-spike RBD subunits. The TAU-2212 blocks ACE2 binding through conformational dynamics. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | TAU-2212 binds quaternary epitope with both arms of the antibody recruited for cross linking intra- and inter-spike RBD subunits. |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, FC |
| Application Notes | High-binding 96 well ELISA plates were coated with 1 µg/mL RBD in PBS ×1 overnight at 4°C. The following day, the coating was discarded, the wells were washed with "washing buffer" and were blocked for 2 h at RT with 200 µL of "blocking buffer", 20 mM EDTA, and 0.05% Tween20. Antibodies were added at a starting concentration of 4 µg/mL, and seven additional 4-fold dilutions in blocking buffer, and incubated for 1 h at RT. The plates were then washed 3 times with washing buffer before adding secondary, anti-human IgG antibody conjugated to HRP diluted 1:5000 in blocking buffer, and incubation for 1 h at RT. Following four additional washes, 100 µL of TMB was added to each well and the absorbance at 650 nm was read after 20 min. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
